Popular Trials
Janus Kinase (JAK) Inhibitor
Ruxolitinib for Precancerous Breast Conditions
This trial is testing if ruxolitinib can change early abnormal breast cells that might turn into cancer. Some participants will take the drug for a short period, while others will not. Afterward, all participants will have surgery to remove the abnormal cells. Ruxolitinib has been evaluated in various clinical trials for treating certain types of breast cancer.
Hormone Therapy
Megestrol + Metformin for Endometrial Cancer Prevention
This trial is testing whether a combination of two drugs, megestrol acetate and metformin, is more effective than megestrol acetate alone in preventing the progression of uterine pre-cancer (endometrial intraepithelial neoplasia) to endometrial cancer.
Selective Estrogen Receptor Modulator
Tamoxifen vs. TamGel for Breast Cancer Risk Reduction
This trial is testing two forms of tamoxifen—a low-dose pill and a skin-applied gel. It targets women with conditions that put them at higher risk for breast cancer. The medication works by blocking estrogen, which can help stop cancer cells from growing. Tamoxifen is a well-established treatment for breast cancer, known for its ability to block estrogen receptors and reduce breast cancer incidence.
Popular Filters
Trials for Enlarged Prostate Patients
Procedure
Traditional vs Top-Down HoLEP for Enlarged Prostate
This trial will compare the two most common types of surgery for treating an enlarged prostate. HoLEP is a newer, less invasive type of surgery that has a shorter hospital stay, but a longer learning curve for surgeons. The "Top-Down" HoLEP technique is a novel technique which offers potential benefits to the Traditional HoLEP procedure, including decreased complexity, a reduced learning curve.
Particle Embolic
Embozene Microspheres for Genital Diseases
The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Beta-3 Adrenoceptor Agonist
Mirabegron +1 More for Overactive Bladder
This trial is testing a new OAB treatment combining a β3-adrenoceptor agonist (mirabegron) with an α-blocker. The goal is to see if this is a safe and effective treatment for OAB symptoms in male patients with BPH.
Thermal Therapy
Prolieve for Enlarged Prostate
The primary objective of the post-marketing study is to collect safety and effectiveness data for 5 years on subjects treated with Prolieve®. The collection of 5-year safety information will be used to evaluate the occurrence of any long-term side effects from the treatment. The collection of long-term effectiveness data on subjects treated with Prolieve® will provide information on the long-term effects of treatment and time to re- treatment (any treatment initiated for BPH since Prolieve'" treatment, including a second treatment with Prolieve").
Trials for Benign Prostatic Hyperplasia Patients
Particle Embolic
Embozene Microspheres for Genital Diseases
The purpose of this project is to evaluate the safety, efficacy, and feasibility of performing prostatic artery embolization (PAE) using endovascular techniques and particle embolics in men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH).
Urethral Expander System
ProVee Urethral Expander System for Benign Prostatic Hyperplasia
This trial is testing a new device called the ProVee Urethral Expander System. It aims to help men who have trouble urinating because of an enlarged prostate. The device works by widening the urethra, making it easier for urine to pass through.
Implantable Device
Zenflow Spring System for Benign Prostatic Hyperplasia
This trial is testing the Zenflow Spring System, a small device that helps men with urinary problems due to an enlarged prostate. It works by keeping the urinary pathway open, making it easier to urinate. The Zenflow Spring System is a novel device designed to alleviate lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH).
Trials With No Placebo
Aromatase Inhibitor
Exemestane for Endometrial Cancer
This trial looks at how well exemestane works in treating patients with endometrial cancer or abnormal cell growth in the endometrium. Exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Anti-diabetic drug
Metformin for Preventing Oral Cancer
This trial tests if metformin hydrochloride can prevent oral cancer in patients with specific mouth lesions. These lesions can increase cancer risk, and metformin may help by slowing cell growth and affecting proteins related to cancer development. Metformin, widely used as a diabetes medication, has recently been reported to reduce cancer risk and improve outcomes in certain cancers.
Hormone Therapy
Levonorgestrel IUS + Everolimus for Endometrial Cancer
This trial tests a hormone-releasing device inside the uterus, alone or with a drug called everolimus, for patients with pre-cancerous growths or early-stage uterine cancer. The device releases a hormone to control cell growth, while everolimus helps stop cancer cells from growing. Everolimus has shown promising results for various types of cancer, including breast cancer.
View More Related Trials
Frequently Asked Questions
Introduction to congenital adrenal hyperplasia
What are the top hospitals conducting congenital adrenal hyperplasia research?
In the realm of clinical trials for congenital adrenal hyperplasia, cutting-edge research is being conducted at several esteemed hospitals across the United States. Located in Bethesda, Maryland, the National Institutes of Health Clinical Center leads the pack with four active trials dedicated to this rare condition. This renowned institution has been at the forefront of congenital adrenal hyperplasia research since recording its first trial back in 1995. Meanwhile, at the University of Wisconsin Hospital and Clinics in Madison, three ongoing trials are currently underway to address this complex disorder. Although they have yet to conduct any prior studies on congenital adrenal hyperplasia, their commitment to breaking new ground is evident.
Similarly committed institutions include The University of North carolina at Chapel Hill and The University of Minnesota/Masonic Cancer Center. Both facilities have two active clinical trials exploring viable treatments for congenital adrenal hyperplasia but have not previously conducted any studies on this specific condition until now.
Even further afield lies Queen's Medical Center located amidst sunny Honolulu where researchers are also dedicating themselves to making strides against this challenging disorder through two current congenital adrenal hyperplasia clinical trials; although Queen's Medical Centre hasn’t explored such experiments before recently.
These top hospitals represent beacons of hope for individuals affected by congenital adrenal hyperplasia as well as testaments to medical advancement on a national scale. Their unwavering dedication toward understanding and treating this rare condition brings us ever closer to improving the lives of those touched by it while reinforcing that progress knows no geographical bounds
Which are the best cities for congenital adrenal hyperplasia clinical trials?
When it comes to congenital adrenal hyperplasia clinical trials, several cities emerge as leading hubs for research and development. Houston, Texas takes the top spot with 14 active trials exploring treatments like Levonorgestrel-Releasing Intrauterine System, Ruxolitinib, Prolieve, and more. New york City closely follows with 12 ongoing studies focused on interventions such as Crinecerfont and Decision Aid. Honolulu, Hawaii also shows promise with 11 active trials investigating options like Decision Aid and Levonorgestrel-Releasing Intrauterine System. Indianapolis, Indiana and Los Angeles, California each have 10 active trials studying various treatments including Tildacerfont and Abiraterone acetate. These cities offer individuals affected by congenital adrenal hyperplasia access to cutting-edge clinical trials that pave the way for advancements in care and potential breakthroughs in treatment options.
Which are the top treatments for congenital adrenal hyperplasia being explored in clinical trials?
Clinical trials are illuminating promising treatments for congenital adrenal hyperplasia, offering hope to those affected by this condition. One standout contender is Chronocort, currently being explored in two active trials for congenital adrenal hyperplasia. Since its debut in 2007, it has been part of five clinical trials dedicated to addressing this disorder. Another potential breakthrough comes from Crinecerfont, a newcomer that has already caught the attention of researchers with two ongoing trials and two all-time studies focused on treating congenital adrenal hyperplasia since its introduction in 2020. As these investigations progress, new avenues may open up for individuals living with this challenging condition.
What are the most recent clinical trials for congenital adrenal hyperplasia?
New developments in clinical trials offer hope for individuals with congenital adrenal hyperplasia. One such trial focuses on sequential dosing, aiming to optimize treatment strategies for this condition. Another study investigates the potential benefits of APG-157 therapy, which could provide a valuable therapeutic option. Additionally, researchers are exploring the use of allogeneic umbilical cord tissue-derived mesenchymal stromal cells as a potential treatment approach. These groundbreaking studies demonstrate ongoing efforts to improve the management and outcomes associated with congenital adrenal hyperplasia.
What congenital adrenal hyperplasia clinical trials were recently completed?
A recent clinical trial investigating treatments for congenital adrenal hyperplasia has yielded promising results. In January 2019, the University of Minnesota successfully completed a trial evaluating the efficacy of subcutaneous hydrocortisone therapy. This important milestone brings us closer to improved management options for individuals with congenital adrenal hyperplasia, highlighting the dedication and progress made by researchers in this field.